Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.

"REOLYSIN(R) administered as a one-hour infusion on a monthly schedule is safe and well-tolerated even in multiple doses," said Principal Investigator Dr. Sanjay Goel of the Montefiore Medical Center and Albert Einstein College of Medicine, New York. "This preliminary data suggests there is anti-tumour activity of REOLYSIN(R) administered as a single agent, and warrants further studies either alone or in combination with cytotoxic chemotherapy, which are currently being planned."

A total of 18 patients were treated in the escalating dosage trial to a maximum daily dose of 3x10(10) TCID(50) in a one-hour infusion. Of the 18 patients treated, eight demonstrated stable disease as measured by RECIST (Response Evaluation Criteria in Solid Tumours) including a patient with progressive breast cancer who experienced a 28.5% shrinkage in tumour volume. The trial was originally designed to demonstrate the safety of a single, one-hour infusion of REOLYSIN(R). During the treatment of the 4th cohort of patients however, Oncolytics applied for and was granted approval to allow subsequent patients to receive repeat monthly treatments of REOLYSIN(R). Of the patients eligible for retreatment, three patients received a range of two to seven one-hour infusions of REOLYSIN(R).

Toxicities possibly related to REOLYSIN(R) treatment in this trial were generally mild (grade 1 or 2) and included chills, fever and fatigue.

The primary objective of the Company's U.S. Phase I trial is to determine the maximum tolerated dose,
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:4/1/2015)... 1, 2015  Hologic, Inc. (NASDAQ: HOLX ) ... 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. ... Company, the trustee, paying agent and conversion agent for ... notes.  This conversion right is subject to the terms ... of December 10, 2007, as supplemented by the second ...
(Date:4/1/2015)... 2015  The first national study to look ... treat attention-deficit/hyperactivity disorder (ADHD) among children ages 4-17 ... with ADHD were receiving behavioral therapy in 2009-2010 ... Prevention (CDC) study, "Treatment of Attention-Deficit/Hyperactivity Disorder among ... in The Journal of Pediatrics provides ...
(Date:4/1/2015)... , April 1, 2015  The fairness of the ... "Company") by Teva Pharmaceutical Industries ("Teva") is being investigated ... law firm.  The investigation focuses on possible breaches of ... Board of Directors of ASPX for agreeing to sell ... Company announced a definitive agreement for Teva to acquire ...
Breaking Medicine Technology:Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8
(Date:4/2/2015)... MedixSafe Vanguard 2 is available, a full line of ... security demands – from stocking a large inventory at ... limited narcotics from falling into the wrong hands. , ... wireless connection to your network and mobile devices that ... Vanguard 2 provides tracking narcotics inventory for ...
(Date:4/1/2015)... April 02, 2015 Robins & Morton ... Living Media Services Building for the New T-Mobile Financial ... five months, including complete demolition of the interior systems, ... addition of 250 parking spaces to accommodate employees. ... his firm was excited to develop such a unique ...
(Date:4/1/2015)... 01, 2015 Levi's® Stadium , located ... the United States. The San Francisco 49ers from the National ... only last year, Levi’s Stadium has been the home of ... been held here thus far include a game from the ... Kings and San Jose Sharks, Wrestlemania 31 and an International ...
(Date:4/1/2015)... Bird B Gone, the leader in bird control ... a complete line of Bird Netting Hardware ... quickly, safely and efficiently. , Having the right hardware ... installation. It’s important to determine exactly what hardware will ... This includes deciding whether to use all stainless steel ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Baby Bellies ... providing the latest information on the top products and ... set the Guinness World Records title for "Mommy Moments” ... of the 1st annual Baby Bellies & Beyond Expo ... and the Guinness World Record will commence at 11:00am ...
Breaking Medicine News(10 mins):Health News:MedixSafe Introduces New High Tech Narcotics Security Solution - Vanguard 2 2Health News:Robins & Morton Transforms Former Southern Living Media Services Building for New T-Mobile Financial Care Call Center 2Health News:Levi's® Stadium Tickets for Super Bowl 50, Kenny Chesney & Jason Aldean, One Direction, Taylor Swift and Luke Bryan Available at Discounted Prices at TicketDown.com 2Health News:Levi's® Stadium Tickets for Super Bowl 50, Kenny Chesney & Jason Aldean, One Direction, Taylor Swift and Luke Bryan Available at Discounted Prices at TicketDown.com 3Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 2Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 3Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3
... and TAMPA, Fla., April 1 Stem Cell Biotherapy ... Los Angeles County Superior Court against the Company,s Co-Founder ... among other things conduct by Nabavi giving rise to ... as a medical doctor, practiced medicine without a license, ...
... April 1 Heavenly Essence, Inc. announces a ... for the ethnic market.The company,s flagship product line, ... of Pure,ity Shampoo and Pure,ity Conditioner, in two ... natural botanicals and hypo-allergenic ingredients, they are now ...
... Call Scheduled for Today at 5:00 p.m. EDT -- ... Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... investors providing for a private placement of up to ... of units consisting of convertible preferred stock and common ...
... were 63 percent more likely to develop the disease, study ... to high levels of traffic pollution have an increased risk ... analyzed the records of 90,000 women in the Nurses Health ... each woman,s home and the nearest major roadways. The results ...
... CitiusTech, a leading provider,of healthcare technology solutions and ... comprehensive program to enable healthcare ISVs to meet,CCHIT requirements ... adoption timeline of 2012 set as part of the ... Act presents a tremendous opportunity for healthcare ISVs to,increase ...
... Hepatology explore the ways that hepatitis B virus ... patients, bodies. Hepatology is a journal published by ... for the Study of Liver Diseases (AASLD). The articles are ... , Both HBV and HCV are global health problems. They ...
Cached Medicine News:Health News:Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t 2Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 2Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 3Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 4Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 5Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 6Health News:Living Near Major Road May Boost Rheumatoid Arthritis Risk 2Health News:CitiusTech Launches Vantage 2012 Program to Enable Healthcare ISVs to Meet CCHIT Requirements & Capture HITECH Act Related Growth Opportunities 2Health News:New studies examine elimination of hepatitis B and C 2
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
Designed to lift corneal cap/flap during corneal lamellar surgery...
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial...
Medicine Products: